
    
      Objectives:

      Primary

      • To assess the safety of one single and one repeated dose of CDR132L in patients with stable
      heart failure of ischemic origin (NYHA 1-3).

      Secondary • To characterize the pharmacokinetic (PK) profile of CDR132L in patients with
      stable heart failure of ischemic origin.

      Exploratory

      • To determine the effect of CDR132L on pharmacodynamic (PD) parameters.
    
  